CMPX is one of three companies open in full. Every company in our coverage universe has a Thesis like this one.
Sign up freeMarket reactionShares rose 11% on Nov 6.
Compass Therapeutics develops antibodies for cancer; its lead, tovecimig, met response and progression endpoints in biliary tract cancer but is not approved.
In COMPANION-002, tovecimig plus paclitaxel improved response (18.0% vs 5.3%) and progression-free survival (HR 0.44) over paclitaxel in second-line biliary tract cancer. Overall survival was not significantly better. In September FDA recommended a survival-benefit trial before a BLA; Compass disagrees and is talking to FDA. CTX-8371 and CTX-10726 report data in the fourth quarter. Cash of $180 million lasts into 2028.
Thesis checklist
1 risk needs attention
In September 2026 FDA recommended a trial showing survival benefit before a BLA; Compass disagrees, citing response and progression results, and plans further FDA engagement.
What would weaken it
COMPANION-002 showed 18.0% response versus 5.3% and median PFS of 4.7 versus 2.6 months (HR 0.44); overall survival was not significant, with crossover in the control arm.
What would weaken it
Expansion-cohort data for CTX-8371 (PD-1 by PD-L1) and initial data for CTX-10726 (PD-1 by VEGF-A) are expected in the fourth quarter of 2026.
What would weaken it
Cash and marketable securities were $180 million at June 30 after $32 million of first-half operating cash use; Compass guides runway into 2028.
What would weaken it
Next decision point
Tests: Agreed path to a BLA
Does FDA accept a BLA based on COMPANION-002, or require a survival trial?
It decides whether tovecimig can reach the market within years.
| Outcome | Evidence to look for | Checklist effect |
|---|---|---|
| Strong | FDA allows a filing on current data. | Checklist effect:Supports a near-term BLA. |
| Inconclusive | FDA allows filing with a confirmatory trial running. | Checklist effect:Delays but keeps the path. |
| Weak | FDA requires a new survival trial first. | Checklist effect:Pushes approval out by years. |
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
The Journal of Clinical Oncology published COMPANION-002: tovecimig plus paclitaxel improved response and progression-free survival, overall survival was not significantly different, and grade 3 or worse side effects were 93.5% versus 64.2%.
FDA's recommendation for a new survival trial blocks a near-term BLA on COMPANION-002, the core of the case.
Source ↗FDA recommended a survival-benefit trial before tovecimig BLA submission, moving the H2 2026 timeline to TBD; Compass disputes the requirement and will re-engage the FDA.
FDA recommended a survival-benefit trial before tovecimig BLA submission. Compass plans further engagement, leaving the submission path unresolved despite positive response-rate and progression-free-survival results.
Source ↗COMPANION-002 met ORR and PFS, but the ITT OS comparison was not statistically significant after 54% of control patients crossed over to receive tovecimig.
The OS secondary endpoint was not statistically significant despite positive ORR and PFS results, leaving the planned BLA path dependent on FDA feedback.
Source ↗Imfinzi or Keytruda with chemotherapy is first-line standard, and Jazz's Ziihera is approved for HER2-positive disease. Tovecimig, a DLL4 by VEGF-A bispecific, improved response and progression-free survival with paclitaxel in second-line patients, but FDA has asked for survival data.
| Product | Target | Administration | Status |
|---|---|---|---|
Company product Tovecimig Compass | DLL4 and VEGF-A | IV | Phase 2/3 |
| Approved | |||
Imfinzi1st-line durvalumab · AstraZeneca | Programmed Death Ligand-1 Blocker | IV · every 4 weeks | Approved |
Keytruda (pembrolizumab)1st-line pembrolizumab · Merck & | PD-1 inhibitor | IV · every 3 weeks | Approved |
Ziihera (zanidatamab-hrii)2nd-line+ zanidatamab-hrii · Jazz | HER2-directed therapy (HER2-positive BTC) | IV · every 3 weeks | Approved |
| In development | |||
CytomX | EpCAM | — | Phase 1 |
sturlimgene erparepvec · Replimune | CTLA-4 | — | Pipeline |
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.